[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,369,164
  • Shares Outstanding, K 51,222
  • Annual Sales, $ 49,080 K
  • Annual Income, $ -109,520 K
  • EBIT $ -191 M
  • EBITDA $ -190 M
  • 60-Month Beta -0.12
  • Price/Sales 27.89
  • Price/Cash Flow N/A
  • Price/Book 79.42

Options Overview Details

View History
  • Implied Volatility 20.09% (-5.18%)
  • Historical Volatility 106.21%
  • IV Percentile 1%
  • IV Rank 0.02%
  • IV High 296.34% on 10/23/25
  • IV Low 20.05% on 04/29/26
  • Expected Move (DTE 5) 1.45 (5.44%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 398
  • Volume Avg (30-Day) 1,347
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 30,999
  • Open Int (30-Day) 26,907
  • Expected Range 25.28 to 28.18

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.37
  • Number of Estimates 5
  • High Estimate $-0.06
  • Low Estimate $-0.59
  • Prior Year $-0.99
  • Growth Rate Est. (year over year) +62.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.66 +43.25%
on 04/24/26
26.84 -0.43%
on 05/06/26
+7.46 (+38.71%)
since 04/08/26
3-Month
14.23 +87.91%
on 02/17/26
26.84 -0.43%
on 05/06/26
+11.83 (+79.40%)
since 02/06/26
52-Week
9.83 +171.92%
on 06/24/25
26.84 -0.43%
on 05/06/26
+14.54 (+119.28%)
since 05/08/25

Most Recent Stories

More News
Are RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KALV : 26.73 (+0.04%)
RMAX : 10.38 (-6.15%)
GBTG : 9.45 (+0.11%)
Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

XOMA : 41.89 (+1.45%)
KALV : 26.73 (+0.04%)
RMAX : 10.38 (-6.15%)
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals...

KALV : 26.73 (+0.04%)
Are KALV, TBRG, UNF, ESQ Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ESQ : 106.83 (-0.44%)
KALV : 26.73 (+0.04%)
TBRG : 25.83 (+0.19%)
UNF : 252.41 (-1.56%)
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , April 29, 2026 /PRNewswire/ -- Ademi LLP is investigating KalVista (NASDAQ: KALV) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

KALV : 26.73 (+0.04%)
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that...

KALV : 26.73 (+0.04%)
Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...

KALV : 26.73 (+0.04%)
ACOG : 6.10 (+0.16%)
SUPN : 51.53 (-1.43%)
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m....

KALV : 26.73 (+0.04%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate...

KALV : 26.73 (+0.04%)
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability

KALV : 26.73 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 26.80
2nd Resistance Point 26.78
1st Resistance Point 26.75
Last Price 26.73
1st Support Level 26.70
2nd Support Level 26.68
3rd Support Level 26.65

See More

52-Week High 26.84
Last Price 26.73
Fibonacci 61.8% 20.35
Fibonacci 50% 18.34
Fibonacci 38.2% 16.33
52-Week Low 9.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.